NCT00687492已完成不适用
Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 8,000
- 试验地点
- 1
- 主要终点
- The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country)
研究概览
简要总结
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •2 or more risk factors (according to NCEP ATP III guideline)
- •Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.
排除标准
- •Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- •Previous enrolment or randomisation of treatment in the present study.
- •Participation in a clinical study during the last 90 days.
结局指标
主要结局
The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country)
时间窗: After collecting all Patient Record Form.
次要结局
- The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets.(After collecting all Patient Record Form.)
- The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables.(After collecting all Patient Record Form.)
- The physician characteristics associated with the allocation of hypercholesterolemia treatment regime.(After collecting all Patient Record Form.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemiaNCT01031277AstraZeneca1,000
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
Centralized Pan-Russian Survey on the Undertreatment of HypercholesterolemiaDyslipidaemiaNCT01221584AstraZeneca1,000
已完成
不适用
Pan-European Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemiaNCT00542867AstraZeneca6,500
撤回
不适用
Dyslipidemia Treatment in Thailand and Cardiovascular OutcomesDyslipidemiaNCT01265836AstraZeneca1,064